Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo.
Department of Medicine, Division of Allergy & Immunology, National Jewish Health, Denver, Colo; Department of Cytobiology and Proteomics, Medical University of Lodz, Lodz, Poland.
J Allergy Clin Immunol. 2018 Sep;142(3):793-803.e8. doi: 10.1016/j.jaci.2017.10.020. Epub 2017 Nov 10.
IL-33 plays an important role in the development of experimental asthma.
We sought to study the role of the IL-33 receptor suppressor of tumorigenicity 2 (ST2) in the persistence of asthma in a mouse model.
We studied allergen-induced experimental asthma in ST2 knockout (KO) and wild-type control mice. We measured airway hyperresponsiveness by using flexiVent; inflammatory indices by using ELISA, histology, and real-time PCR; and type 2 innate lymphoid cells (ILC2s) in lung single-cell preparations by using flow cytometry.
Airway hyperresponsiveness was increased in allergen-treated ST2 KO mice and comparable with that in allergen-treated wild-type control mice. Peribronchial and perivascular inflammation and mucus production were largely similar in both groups. Persistence of experimental asthma in ST2 KO mice was associated with an increase in levels of thymic stromal lymphopoietin (TSLP), IL-9, and IL-13, but not IL-5, in bronchoalveolar lavage fluid. Expectedly, ST2 deletion caused a reduction in IL-13 CD4 T cells, forkhead box P3-positive regulatory T cells, and IL-5 ILC2s. Unexpectedly, ST2 deletion led to an overall increase in innate lymphoid cells (CD45linCD25 cells) and IL-13 ILC2s, emergence of a TSLP receptor-positive IL-9 ILC2 population, and an increase in intraepithelial mast cell numbers in the lung. An anti-TSLP antibody abrogated airway hyperresponsiveness, inflammation, and mucus production in allergen-treated ST2 KO mice. It also caused a reduction in innate lymphoid cell, ILC2, and IL-9 and IL-13 ILC2 numbers in the lung.
Genetic deletion of the IL-33 receptor paradoxically increases TSLP production, which stimulates the emergence of IL-9 and IL-13 ILC2s and mast cells and leads to development of chronic experimental asthma. An anti-TSLP antibody abrogates all pathologic features of asthma in this model.
IL-33 在实验性哮喘的发展中发挥重要作用。
我们旨在研究白细胞介素-33 受体抑制肿瘤发生 2(ST2)在小鼠模型中哮喘持续存在中的作用。
我们研究了 ST2 敲除(KO)和野生型对照小鼠中变应原诱导的实验性哮喘。我们使用 FlexiVent 测量气道高反应性;通过 ELISA、组织学和实时 PCR 测量炎症指数;并通过流式细胞术测量肺单细胞制剂中的 2 型固有淋巴细胞(ILC2)。
在变应原处理的 ST2 KO 小鼠中,气道高反应性增加,与变应原处理的野生型对照小鼠相当。两组的支气管周围和血管周围炎症和粘液产生基本相似。在 ST2 KO 小鼠中,实验性哮喘的持续存在与支气管肺泡灌洗液中胸腺基质淋巴生成素(TSLP)、IL-9 和 IL-13 水平的增加有关,但与 IL-5 无关。预期的是,ST2 缺失导致 IL-13 CD4 T 细胞、叉头框 P3 阳性调节性 T 细胞和 IL-5 ILC2 的减少。出乎意料的是,ST2 缺失导致固有淋巴细胞(CD45linCD25 细胞)和 IL-13 ILC2 的总体增加、TSLP 受体阳性 IL-9 ILC2 群体的出现以及肺上皮内肥大细胞数量的增加。抗 TSLP 抗体消除了变应原处理的 ST2 KO 小鼠的气道高反应性、炎症和粘液产生。它还导致肺中固有淋巴细胞、ILC2、IL-9 和 IL-13 ILC2 的数量减少。
IL-33 受体的基因缺失出人意料地增加了 TSLP 的产生,这刺激了 IL-9 和 IL-13 ILC2 和肥大细胞的出现,并导致慢性实验性哮喘的发展。抗 TSLP 抗体消除了该模型中哮喘的所有病理特征。